Get the Stockscreener App
0.953
3.38%
-0.0333
After Hours:
.99
0.037
+3.88%
Immunic Inc stock is traded at $0.953, with a volume of 1.72M.
It is down -3.38% in the last 24 hours and down -12.57% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
See More
Previous Close:
$0.9863
Open:
$0.9863
24h Volume:
1.72M
Relative Volume:
1.71
Market Cap:
$85.85M
Revenue:
-
Net Income/Loss:
$-93.61M
P/E Ratio:
-0.4517
EPS:
-2.11
Net Cash Flow:
$-71.16M
1W Performance:
-9.24%
1M Performance:
-12.57%
6M Performance:
-34.73%
1Y Performance:
-21.24%
1-Day Range:
$0.95
$1.00
1-Week Range:
$0.95
$1.10
52-Week Range:
$0.95
$2.11
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.953 | 85.85M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
IMUX Stock Touches 52-Week Low at $0.97 Amid Market Challenges - MSN
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 14.9% in December - MarketBeat
Jane Street Group LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $12.67 - Defense World
Immunic, Inc. (NASDAQ:IMUX) Receives $12.67 Average PT from Brokerages - MarketBeat
Immunic eyes transformative year ahead for MS therapy vidofludimus calciumICYMI - Proactive Investors Australia
Immunic ‘on track’ with MS clinical trials testing vidofludimus calcium - Multiple Sclerosis News Today
Immunic (NASDAQ:IMUX) Earns “Buy” Rating from D. Boral Capital - Defense World
Immunic COO Jason Tardio discusses key 2024 highlights, 2025 milestones - Proactive Investors Australia
Immunic eyes key data readout from multiple sclerosis trial in 2025 - Proactive Investors Australia
D. Boral Capital Reaffirms "Buy" Rating for Immunic (NASDAQ:IMUX) - MarketBeat
Immunic Highlights 2024 Accomplishments and Upcoming Milestones - PR Newswire
State Street Corp Boosts Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.80 - Defense World
Immunic CEO Daniel Vitt secures new employment terms - Investing.com
Immunic CEO Daniel Vitt secures new employment terms By Investing.com - Investing.com South Africa
Immunic, Inc. (NASDAQ:IMUX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - Defense World
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 10.3% in November - MarketBeat
Immunic CEO Dr Daniel Vitt on successful 2024, with more to come in the year ahead - Proactive Investors Australia
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - The Eastern Progress Online
Janus Henderson Group PLC Sells 1,974,566 Shares of Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic CSO discusses breaking the IBD stigma to mark Crohn's and Colitis Awareness Week - Proactive Investors UK
Broad Benefits Of Immunic MS Drug Could Transform Treatment - News & Insights
B. Riley Has Bearish Forecast for Immunic FY2024 Earnings - Defense World
B. Riley Estimates Immunic's FY2024 Earnings (NASDAQ:IMUX) - MarketBeat
FY2024 Earnings Estimate for Immunic Issued By HC Wainwright - Defense World
IMUXImmunic, Inc. Latest Stock News & Market Updates - StockTitan
HC Wainwright Begins Coverage on Immunic (NASDAQ:IMUX) - Defense World
HC Wainwright Estimates Immunic’s Q4 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. to Participate in Investor Conference in December - The Malaysian Reserve
Immunic to present at Piper Sandler 36th Annual Healthcare Conference - Proactive Investors USA
What is HC Wainwright's Estimate for Immunic Q4 Earnings? - MarketBeat
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook - Investing.com Nigeria
H.C. Wainwright bullish on Immunic stock—Phase 3 MS drug de-risks outlook By Investing.com - Investing.com South Africa
Immunic initiated with a Buy at H.C. Wainwright - TipRanks
Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Average Price Target from Analysts - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.7% in October - Defense World
Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):